Heron Therapeutics Insider Buying Signals Confidence Amid Volatile Sentiment 【News Flash】
Heron Therapeutics insiders keep buying as the stock hits a 52‑week low. Forbes’ disciplined trades suggest the stock may be undervalued, hinting at a potential breakout if the biotech’s drug‑delivery platform delivers.
3 minutes to read